Disease-modifying drugs for multiple sclerosis: Current and future aspects

Expert Opinion on Pharmacotherapy

Volumn 7, Issue SUPPL. 1, 2006, Pages S1-S9

  Freedman, Mark S ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; CANNABIS; CLADRIBINE; DACLIZUMAB; FINGOLIMOD; GLATIRAMER; IBUPROFEN; INTERFERON BETA SERINE; LAMOTRIGINE; LAQUINIMOD; NATALIZUMAB; PARACETAMOL; PLACEBO; RILUZOLE; SIMVASTATIN; TERIFLUNOMIDE;

CHEST TIGHTNESS; CLINICAL TRIAL; DISEASE COURSE; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MEGADOSE; DYSPNEA; FLU LIKE SYNDROME; HEART PALPITATION; HUMAN; INJECTION SITE REACTION; LIPOATROPHY; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NAUSEA; PATHOPHYSIOLOGY; PHARMACOGENOMICS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; REVIEW; STEM CELL TRANSPLANTATION; SWEAT GLAND DISEASE; SYMPTOMATOLOGY; TREMOR; URTICARIA;

EID: 33750051050     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.1.S1     Document Type: Review

References (61)

1. GLABINSK AR, RANSOHOFF RM: Targeting the chemokine system for multipe sclerosis treatment. Curr. Opin. Investig. Drugs (2001) 2(12):1712-1719.
2. COMPSTON A, COLES A: Multiple sclerosis. Lancet (2002) 359(9313):1221-1231.
3. LUBLIN FD, REINGOLD SC: Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisery Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology (1996) 46(4):907-911.
4. KOBELL G, PUGLIATTI M: Cost of multiple sclerosis in Europe. Eur. J. Neurol. (2005) 12(Suppl. 1):63-67.
5. NOSEWORTHY J, LUCCINETTI C, RODRIGUEZ M, WEINSHENKER BG: Multiple sclerosis. N. Engl. J. Med. (2000) 343(13):938-952.
6. TRAPP BD, PETERSON J, RANSOHOFF RM et al.: Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. (1998) 338(5):278-285.
7. CHOFFLON M: Mechanisms of action for treatments in multiple sclerosis. Does a heterogeneous disease demand a multi-targeted therapeutic approach? Biodrugs (2005) 19(5):299-308.
8. WEINSHENKER B: Western versus optic-spinal MS: two diseases, one treatment? Neurology (2005) 64(4):594-595.
9. BUFILL E, BLESA R, GALAN I, DEAN G: Prevalence of multiple sclerosis in the region of Osona, Catalonia, northern Spain. J. Neurol. Neurosurg. Psychiatry (1995) 58(5):577-581.
10. ROSATI G, AIELLO I, PIRASTRU MI et al.: Epidemiology of multiple sclerosis in Northwestern Sardinia: further evidence for higher frequency in Sardinians compared to other Italians. Neuroepidemiology (1996) 15(1):10-19.
11. MAYR WT, PITTOCK SJ, McCLELLAND RL et al.: Incidence and prevalence of multiple sclerosis in Olmstead County, Minnesota, 1985-2000. Neurology (2003) 61(10):1373-1377.
12. POSER CM, PATY DW, SCHEINBERG L et al.: New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. (1983) 13(3):227-231.
13. MCDONALD WI, COMPSTON A, EDAN G et al.: Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann. Neurol. (2001) 50(1):121-127.
14. POLMAN CH, REINGOLD SC, EDAN C et al.: Diagnostic criteria for multiple sclerosis: 2005 revisions to the 'McDonald criteria.' Ann. Neurol. (2005) 56(6):840-864.
15. BREX PA, CICCARELLI O, O'RIORDAN JI et al.: A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N. Engl. J. Med. (2002) 346(3):158-164.
16. KURTZKE JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology (1983) 33(11):1444-1452.
17. WATSON CM, DAVISON AN, BAKER D: Suppression of demyelination by mitoxantrone. Int. J. Immunopharmacol. (1991) 13(7):923-930.
18. HARTUNG HP, GONSETTE R, KONIG N et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicenter trial. Lancet (2002) 360(9350):2018-2025.
19. MURRAY TJ: Diagnosis and treatment of multiple sclerosis. Br. Med. J. (2006) 332(7540):525-527.
20. BJARTMAR C, TRAPP BD: Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox. Res. (2003) 5(1-2):157-164.
21. JACOBS LD, BECK RW, SIMON JH et al.: Intramuscular infereon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N. Engl. J. Med. (2000) 343(13):894-898.
22. COMI G, FILIPPI M, BARKHOF F et al.: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet (2001) 357(9268):1576-1582.
23. KAPPOS L, POLMAN C, FREEDMAN MS et al.: Betaferon in newly emerging multiple sclerosis for initial treatment (BENEFIT) clinical results. Presented at The 21st Congress of the European Committee for Treatment and Research in Multiple Sclerosis/ 10th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis. Thessaloniki, Greece (28 September - 1 October 2005).
24. PITTOCK SJ, McCLELLAND RL, MAYR WT et al.: Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann. Neurol. (2004) 56(2):303-306.
25. IFN-B MULTIPLE SCLEROSIS STUDY GROUP: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology (1993) 43(4):655-661.
26. PATY DW, LI DK, UBC MS/MRI STUDY GROUP AND THE IFN-B MULTIPLE SCLEROSIS STUDY GROUP: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis II: MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology (1993) 43(4):662-667.
27. IFN-B MULTIPLE SCLEROSIS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology (1995) 45(7):1277-1285.
28. PRISMS STUDY GROUP: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet (1998) 352(9139):1498-1504.
29. LI DK, PATY DW: Magnetic resonance imaging results of the PRISMS trial - a randomized, double-blind, placebo-controlled study of interferon-beta 1a in relapsing-remitting multiple sclerosis: prevention of relapses and disability by interferon-beta 1a subcutaneously in multiple sclerosis. Ann. Neurol. (1999) 46(2):197-206.
30. PRISMS STUDY GROUP AND THE UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology (2001) 56(12):1628-1636.
31. 1a therapy in patients with relapsing-remitting MS. Neurology (2006) (In Press).
32. SIMON JH, JACOBS LD, CAMPION M et al.: Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann. Neurol. (1998) 43(1):79-87.
33. RUDICK RA, GOODKIN DE, JACOBS LD et al.: Impact of interferon beta-1a on neurologic disability in relapsing multiple sderosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology (1997) 49(2):358-363.
34. JACOBS LD, COOKFAIR DL, RUDICK RA et al.: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann. Neurol. (1996) 39(3):285-294.
35. ONCE WEEKLY INTERFERON FOR MS STUDY GROUP: Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS study. Neurology (1999) 53(4):679-686.
36. SCHWID S R, THORPE J, SHARIEF M et al.: Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE study. Arch. Neurol. (2005) 62(5):785-792.
37. PANITCH H, GOODIN DS, FRANCIS G et al.: Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology (2002) 59(10):1496-1506.
38. DURELLI L, VERDUN E, BARBERO P et al.: Independent Comparison of Interferon (INCOMIN) Trial Study Group. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multi-centre study (INCOMIN). Lancet (2002) 359(9316):1453-1460.
39. JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a Phase III multicenter, double-blind placebo-controlled trial. Neurology (1995) 45(7):1268-1276.
40. JOHNSON KP, BROOKS BR, COHEN JA et al.: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology (1998) 50(3):701-708.
41. POLMAN CH, O'CONNOR PW, HAVRDOVA E et al.: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. (2006) 354(9):899-910.
42. RUDICK RA, CUTTER GR, BAIER M et al.: Estimating long-term effects of disease-modifying drug therapy in multiple sclerosis patients. Mult. Scler. (2005) 11(6):626-634.
43. KAPPOS L, RADUE EW, ANTEL J et al.: FTY720 in relapsing MS: results of a double-blind placebo-controlled trial with a novel oral immunomodulator. Presented at The 15th European Neurological Society Meeting. Vienna (18 - 22 June 2005).
44. WU X, DASTIDAR P, KUUSISTO H et al.: Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MS. Acta Neurol. Scand. (2005) 112(4):242-247.
45. DURELLI L, CLERICO M: The importance of maintaining effective therapy in multiple sclerosis. J. Neurol. (2005) 252(Suppl. 5):iii38-iii43.
46. RIO J, PORCEL J, TELLEZ N et al.: Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis. Mult. Scler. (2005) 11(3):306-309.
47. O'ROURKE KE, HUTCHINSON M: Stopping beta-interferon therapy in multiple sclerosis: an analysis of stopping patterns. Mutt. Scler. (2005) 11(1):46-50.
48. MOHR DC, GOODKIN DE, LIKOSKY W et al.: Therapeutic expectations of patients with multiple sclerosis upon initiating interferon beta-1b: relationship to adherence to treatment. Mult. Scler. (1996) 2(5):222-226.
49. MOHR DC, GOODKIN DE, LIKOSKY W et al.: Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch. Neurol. (1997) 54(5):531-533.
50. CHITNIS T, IMITOLA J, KHOURY SJ: Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr. Drug Targets Immune Endocr. Metabol. Disord. (2005) 5(1):11-26.
51. LANGTRY HD, LAMB HM: Cladribine: a review of its use in multiple sclerosis. Biodrugs (1998) 9(5):419-433.
52. SIPE JC: Cladribine for multiple sclerosis: review and current status. Expert Rev. Neurother. (2005) 5(6):721-727.
53. LI DK, O'CONNER P, FREEDMAN M et al.: Oral teriflunomide is safe and effective in multiple sclerosis with relapses: results of a randomised, placebo-controlled Phase II study. Mult. Scler. (2004) 10(Suppl. 2): P685.
54. O'CONNOR PW, LI D, FREEDMAN MS et al.: A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology (2006) 66(6):894-900.
55. POLMAN C, BARKHOF F, SANDBERG-WOLLHEIM M et al.: Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology (2005) 64(6):987-991.
56. VOLLMER T, KEY L, DURKALSKI V et al.: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet (2004) 363(9421):1607-1608.
57. BIELEKOVA B, RICHERT N, HOWARD T et al.: Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc. Natl. Acad. Sci. USA (2004) 101(23):8705-8708.
58. RIECKMANN P: Neurodegeneration and clinical relevance for early treatment in multiple sclerosis. Int. MS J. (2005) 12(2):42-51.
59. KALKERS NF, BARKHOF F, BERGERS E et al.: The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult. Scler. (2002) 8(6):532-533.
60. KARUSSIS D, GRIGORIADIS S, POLYZOIDOU E et al.: Neuroprotection in multiple sclerosis. Clin. Neurol. Neurosurg. (2006) 108(3):250-254.
61. MACCIARDI F, BONESCHI FM, COHEN D: Pharmcogenetics of autoimmune diseases: research issues in the case of multiple sclerosis and the role of IFN-beta. J. Autoimmun. (2005) 25(Suppl):1-5.